CMS Open Payments · Program Year 2024
Instylla, Inc.
Instylla, Inc. reported $1,530,797.17 across General Payments, Research, and Ownership to 124 physicians and teaching hospitals across 272 transactions.
- $1.5M Above-median payer
- All-tracks total
- 272 Above-median volume
- Transactions
- 124 Below-median reach
- Recipients
- −$43.4K
- General Payments vs PY2023
Instylla, Inc. reported $1,530,797.17 across all CMS Open Payments tracks (General + Research + Ownership) to 124 physicians and teaching hospitals in Program Year 2024 - ranking #517 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $144,155.53, averaging $12.3K per recipient.
How Instylla, Inc.'s $1.5M all-tracks total breaks down
Instylla, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
24/100
Total payments
F
24/100
Transaction volume
F
12/100
Physician reach
F
11/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer instylla-inc Instylla, Inc.
$1.5M · #517/1,925 · 0.0% industry · PY2024
- TOT $1.5M
- RANK #517
- SHARE 0.0%
- TXN 272
- RCP 124
- CAT 4
- GEN $144.2K
- ΔGEN −$43.4K
- TOP1 17.4%
- PY 2024
Volume peers
Nearest volume peer: Balt USA, LLC ($1.5M)
Instylla, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Instylla, Inc.'s CMS-reported General Payments decreased by $43.4K (−23.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: INSTYLLA, INC.PY2023: INSTYLLA, INC.PY2024: Instylla, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $187,579.28
- PY2024
- $144,155.53
What the Data Shows for Instylla, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Instylla, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 4 general-payment categories charted below, "Consulting Fee" is the largest at $125.5K across 44 transactions, 87.1% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Instylla, Inc.'s 4-category general-payment breakdown at $125.5K, 87.1% of the reported total.
Instylla, Inc. reports 4 general-payment categories - the top three are Consulting Fee (87.1%), Space Rental or Facility Fees (6.7%), and Travel and Lodging (4.3%). The remaining 1 category make up 1.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Instylla, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $125.5K | 44 | 87.1% |
| Space Rental or Facility Fees | $9.7K | 1 | 6.7% |
| Travel and Lodging | $6.2K | 23 | 4.3% |
| Food and Beverage | $2.8K | 56 | 1.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $102,992.55 (71.4%) of $144,155.53 in this company's General Payments records across 46 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Instylla, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Salomao Faintuch
$25,142.48 across 6 reported transactions
- 2
David P Tahour
$22,803.51 across 12 reported transactions
- 3
Kei Yamada
$22,667.48 across 7 reported transactions
- 4
Dmitry J Rabkin
$21,317.48 across 6 reported transactions
- 5
Suvranu Ganguli
$11,061.60 across 11 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Instylla, Inc. ranks #517 of 1,925 by total payments (top 27% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #960 of 1,838 by HHI (bottom 48% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Zavation Medical Products, LLC : $696.6K total payments, HHI 1183
- Topcon Healthcare, Inc. : $675.4K total payments, HHI 1183
- MicroPort Orthopedics Inc : $2.8M total payments, HHI 1182
- Fuse Medical, Inc. : $236.2K total payments, HHI 1179
- Valneva Usa, Inc. : $43.5K total payments, HHI 1173
- Bracco Diagnostics Inc. : $410.3K total payments, HHI 1171
- Instylla, Inc. (this company) : $144.2K total payments, HHI 1169
- Reprise Biomedical, Inc. : $117.0K total payments, HHI 1168
- DentalEZ Alabama, Inc. : $5.9K total payments, HHI 1168
- Hollister Incorporated : $45.3K total payments, HHI 1167
- Kamada Ltd. : $83.4K total payments, HHI 1166
- Pulpdent Corporation : $80.0K total payments, HHI 1162
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Instylla, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Instylla, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Instylla, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Collegium Pharmaceutical, Inc.
Invivyd Inc
ExThera Medical Corporation
Fresenius Kabi USA, LLC
Zevra Therapeutics Inc
Put this to use
Instylla, Inc. ranks #517 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Instylla, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Instylla, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.